Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
DERM
$8.7
$
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Next Earnings
2026-02-25
Beta
0.819
Average Volume
Market Cap
Last Dividend
CIK
0001867066
ISIN
US48115J1097
CUSIP
48115J109
CEO
Claude Maraoui
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Full Time Employees
41
IPO Date
2021-11-12
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Journey Medical Corporation (NASDAQ:DERM) Receives $12.17 Consensus Target Price from Brokerages | Shares of Journey Medical Corporation (NASDAQ: DERM - Get Free Report) have been assigned a consensus recommendation of "Hold" from the five ratings firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a | Defense World | 2026-02-13 02:08:58 |
| Financial Review: Zevra Therapeutics (NASDAQ:ZVRA) versus Journey Medical (NASDAQ:DERM) | Zevra Therapeutics (NASDAQ: ZVRA - Get Free Report) and Journey Medical (NASDAQ: DERM - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership. Profitability This table compares Zevra Therapeutics and | Defense World | 2025-12-26 01:27:02 |
| Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology | Clinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on skin, GI tract or vaginal microbiota FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea in adults SCOTTSDALE, Ariz., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that results from the Phase 1 clinical trial (DFD-29-CD-006) assessing the impact of low-dose oral minocycline (“DFD-29” or commercially known as “Emrosi™) on skin, gastrointestinal (“GI”) and vaginal microflora in healthy adults were published in the Journal of Drugs in Dermatology, a leading peer-reviewed publication in clinical dermatology. | GlobeNewsWire | 2025-12-10 08:30:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 424B3 | 2026-01-23 | 2026-01-23 | View Filing |
| 424B3 | 2026-01-23 | 2026-01-23 | View Filing |
| EFFECT | 2026-01-21 | 2026-01-22 | View Filing |
| S-3 | 2026-01-15 | 2026-01-15 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-09-26 | 2025-09-26 | View Filing |
| 8-K | 2025-08-28 | 2025-08-28 | View Filing |
| 424B3 | 2025-08-28 | 2025-08-28 | View Filing |
| 4 | 2025-08-26 | 2025-08-26 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| 10-Q | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-08-12 | 2025-08-12 | View Filing |
| 4 | 2025-08-07 | 2025-08-07 | View Filing |
| 4 | 2025-08-07 | 2025-08-07 | View Filing |
| 4 | 2025-08-07 | 2025-08-07 | View Filing |
| 4 | 2025-08-07 | 2025-08-07 | View Filing |
| 4 | 2025-08-07 | 2025-08-07 | View Filing |
| 8-K | 2025-07-14 | 2025-07-14 | View Filing |
| 4 | 2025-07-07 | 2025-07-07 | View Filing |
| 4 | 2025-07-07 | 2025-07-07 | View Filing |
| 4 | 2025-07-07 | 2025-07-07 | View Filing |
| 4 | 2025-07-07 | 2025-07-07 | View Filing |
| 4 | 2025-07-07 | 2025-07-07 | View Filing |
| 8-K | 2025-06-26 | 2025-06-26 | View Filing |
| 8-K | 2025-06-24 | 2025-06-24 | View Filing |
| 4 | 2025-06-20 | 2025-06-20 | View Filing |
| 4 | 2025-06-20 | 2025-06-20 | View Filing |
| 4 | 2025-06-20 | 2025-06-20 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| 10-Q | 2025-05-15 | 2025-05-15 | View Filing |
| 8-K | 2025-05-14 | 2025-05-14 | View Filing |
| SC 13G | 2025-05-13 | 2025-05-13 | View Filing |
| 4 | 2025-05-05 | 2025-05-05 | View Filing |
| 4 | 2025-05-05 | 2025-05-05 | View Filing |
| 4 | 2025-05-05 | 2025-05-05 | View Filing |
| DEFA14A | 2025-04-29 | 2025-04-29 | View Filing |
| DEF 14A | 2025-04-29 | 2025-04-29 | View Filing |
| PRE 14A | 2025-04-18 | 2025-04-18 | View Filing |
| 4 | 2025-04-16 | 2025-04-16 | View Filing |
| 4 | 2025-04-16 | 2025-04-16 | View Filing |
| 3 | 2025-04-04 | 2025-04-04 | View Filing |
| 8-K | 2025-04-03 | 2025-04-03 | View Filing |
| 10-K | 2025-03-27 | 2025-03-26 | View Filing |
| 8-K | 2025-03-26 | 2025-03-26 | View Filing |
| 8-K | 2025-03-24 | 2025-03-24 | View Filing |
| 4 | 2025-03-11 | 2025-03-11 | View Filing |
| 4 | 2025-03-10 | 2025-03-10 | View Filing |
| 4 | 2025-03-05 | 2025-03-05 | View Filing |
| 4 | 2025-02-24 | 2025-02-24 | View Filing |
| 8-K | 2025-02-05 | 2025-02-05 | View Filing |
| SC 13G | 2024-11-29 | 2024-11-29 | View Filing |
| 10-Q | 2024-11-12 | 2024-11-12 | View Filing |
| 8-K | 2024-11-12 | 2024-11-12 | View Filing |
| 8-K | 2024-11-04 | 2024-11-04 | View Filing |
| UPLOAD | 2024-09-09 | 2024-09-09 | View Filing |
| CORRESP | 2024-08-22 | 2024-08-22 | View Filing |
| UPLOAD | 2024-08-21 | 2024-08-21 | View Filing |
| 10-Q | 2024-08-13 | 2024-08-12 | View Filing |
| 8-K | 2024-08-12 | 2024-08-12 | View Filing |
| 4 | 2024-08-01 | 2024-08-01 | View Filing |
| 4 | 2024-07-23 | 2024-07-23 | View Filing |
| 4 | 2024-07-23 | 2024-07-23 | View Filing |
| 3 | 2024-07-19 | 2024-07-19 | View Filing |
| S-8 | 2024-07-19 | 2024-07-18 | View Filing |
| 8-K | 2024-07-12 | 2024-07-12 | View Filing |
| 4 | 2024-07-10 | 2024-07-10 | View Filing |
| 4 | 2024-07-10 | 2024-07-10 | View Filing |
| 4 | 2024-07-10 | 2024-07-10 | View Filing |
| 4 | 2024-07-10 | 2024-07-10 | View Filing |
| 8-K | 2024-06-25 | 2024-06-25 | View Filing |
| 4 | 2024-05-31 | 2024-05-31 | View Filing |
| 3 | 2024-05-31 | 2024-05-31 | View Filing |
| 10-Q | 2024-05-14 | 2024-05-14 | View Filing |
| 8-K | 2024-05-13 | 2024-05-13 | View Filing |
| 8-K | 2024-05-01 | 2024-05-01 | View Filing |
| DEFA14A | 2024-04-29 | 2024-04-29 | View Filing |
| DEF 14A | 2024-04-29 | 2024-04-29 | View Filing |
| 10-K | 2024-03-29 | 2024-03-28 | View Filing |
| 4 | 2024-03-27 | 2024-03-27 | View Filing |
| 4 | 2024-03-25 | 2024-03-25 | View Filing |
| 4 | 2024-03-25 | 2024-03-25 | View Filing |
| 4 | 2024-03-25 | 2024-03-25 | View Filing |
| 8-K | 2024-03-21 | 2024-03-21 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Volume Gap | 35.31% | 1 | 651 | 0.05 | 0.08 | 30.51 |
| Larry Williams PercentR Strategy | 35.07% | 0.99 | 153 | 0.07 | 0.14 | 30.26 |
| Williams PercentR Strategy | 34.47% | 1.01 | 290 | 0.07 | 0.16 | 29.67 |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxx% | xxxx | x | x | xxxx | xxxx |
| xxxx | xxxxxxx% | x | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |